David Blaine Ridley | Scholars@Duke

David Blaine Ridley
Professor of the Practice of Business Administration

David Ridley is the Faculty Director for Health Sector Management at Duke University’s Fuqua School of Business. He studies health care innovation, production, and prices. He is especially interested in how to encourage development of drugs and vaccines for neglected diseases. David was the lead author of the paper proposing the priority review voucher program which became law and created a market of more than a billion dollars to encourage drug development for neglected diseases. His research has been funded by the Bill & Melinda Gates Foundation and the National Institutes of Health. David teaches courses on health care policy and strategy to Duke University graduate students. He received a doctorate in economics from Duke University.

Current Appointments & Affiliations

Professor of the Practice of Business Administration, Fuqua School of Business, Duke University 2017
Professor of the Practice of Economics, Economics, Trinity College of Arts & Sciences 2018
Associate of the Duke Initiative for Science & Society, Duke Science & Society, Initiatives 2017
Executive Core Faculty Member, Duke-Margolis Center for Health Policy, Duke - Margolis Center For Health Policy, Initiatives 2019

Contact Information

100 Fuqua Drive, Durham, NC 27708-0120
Duke Box 90120, 100 Fuqua Drive, Durham, NC 27708-0120
david.ridley@duke.edu (919) 660-3784
Fuqua Faculty Profile
Professional Page

Background
Education, Training, & Certifications
- Ph.D., Duke University 2001
- M.A., Duke University 1995
- B.A., University of Missouri, Columbia 1993
Previous Appointments & Affiliations
- Professor of the Practice of Business Administration, Fuqua School of Business, Duke University 2019
- Associate Professor of the Practice of Business Administration, Fuqua School of Business, Duke University 2013 - 2017
- Assistant Professor in the Department of Economics, Economics, Trinity College of Arts & Sciences 2006 - 2014
- Assistant Professor of Business Administration, Fuqua School of Business, Duke University 2006 - 2013
- Assistant Professor of the Practice of Business Administration, Fuqua School of Business, Duke University 2004 - 2006
Recognition
In the News
- JUN 10, 2021 Fuqua School of Business
  
  Launch Prices for New Drugs Have Doubled Since 2005
- JUN 18, 2018 Fuqua School of Business
  
  Federal Review Protocol Suggested by Duke Faculty Approves Drug for Neglected Tropical Disease
- JAN 26, 2018 The Wall Street Journal
  
  The economist behind the ‘priority review voucher,’ which advances treatments for neglected diseases.
- DEC 14, 2017 Fuqua School of Business
  
  When the U.S. Spends More on Fighting a Disease, the Rest of the World Spends Less
- AUG 9, 2017 Fuqua School of Business
  
  Fuqua Insights: A Proposal to Generate Insecticides that Could Save Millions of Lives
- JUN 27, 2016 The New York Times
  
  Low prices for vaccines can come at a great cost
- MAY 5, 2016
  
  Fuqua Research Urges Caution in Expansion of Drug Development Incentive Program
- MAY 5, 2016 Duke Today
  
  Fuqua Research Urges Caution in Expansion of Drug Development Incentive Program
- MAR 28, 2016
  
  Infectious Disease Symposium Convenes at Duke April 1
- MAR 28, 2016 Duke Today
  
  Infectious Disease Symposium Convenes at Duke April 1
- FEB 9, 2016
  
  Fuqua Professor David Ridley Explores Tensions in the Vaccine Market
- FEB 8, 2016 Duke Today
  
  Fuqua Professor David Ridley Explores Tensions in the Vaccine Market
- SEP 3, 2015
  
  Fuqua Research on Why Timing Is Important in Launching New Pharmaceuticals
- SEP 3, 2015 Duke Today
  
  Fuqua Research on Why Timing Is Important in Launching New Pharmaceuticals
- AUG 20, 2015 Triangle Business Journal
  
  How Duke Fuqua profs connect to a $350M pharma transaction
- AUG 20, 2015 NPR
  
  Price rises for ticket to a quicker drug review by FDA
- MAR 6, 2015
  
  DIW Office Connects Duke Experts to Washington
- OCT 28, 2014 The Washington Post
  
  David Ridley: The little-known federal program that could speed up an Ebola cure
- OCT 13, 2014 The Boston Globe
  
  Editorial: Containing Ebola will require powerful new weapons
- OCT 8, 2014 The Philadelphia Inquirer
  
  David Ridley: Give drug companies more incentive to fight Ebola
- OCT 8, 2014 the Philadephia Inquirer
  
  Give Drug Companies More Incentive to Fight Ebola
Expertise
Subject Headings
Research
Selected Grants
- The Next Phase of Antimicrobial Resistance Payment Policy awarded by Wellcome Trust 2022 - 2023
- Transferable Exclusivity Voucher (TEV) Program for Neglected Diseases (Phase 3 Supplement) awarded by Bill and Melinda Gates Foundation 2018 - 2022
- Transforming the Market to Address Antimicrobial Resistance awarded by Schmidt Futures 2020 - 2021
- Gates Phase II awarded by Bill and Melinda Gates Foundation 2019 - 2021
- Sustainable Biodefense Industrial Base for the Assistant Secretary for Preparedness and Response awarded by Mitre Corporation 2016 - 2019
- GHTC R&D Mapping awarded by PATH 2016 - 2017
- Determinants and Consequences of Alcohol Consumption awarded by National Institutes of Health 2005 - 2011
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Ridley, David B., Pranav Ganapathy, and Hannah E. Kettler. “US Tropical Disease Priority Review Vouchers: Lessons In Promoting Drug Development And Access.” Health Affairs (Project Hope) 40, no. 8 (August 2021): 1243–51. https://doi.org/10.1377/hlthaff.2020.02273.
    Full Text
  - Ridley, D. B., and C. Y. Lee. “Does medicare reimbursement drive up drug launch prices?” Review of Economics and Statistics 102, no. 5 (December 1, 2020): 980–93. https://doi.org/10.1162/rest_a_00849.
    Full Text
  - Kyle, M. K., D. B. Ridley, and S. Zhang. “Strategic interaction among governments in the provision of a global public good.” Journal of Public Economics 156 (December 1, 2017): 185–99. https://doi.org/10.1016/j.jpubeco.2017.10.009.
    Full Text Open Access Copy
  - Ridley, David B., Jeffrey L. Moe, and Nick Hamon. “A Voucher System To Speed Review Could Promote A New Generation Of Insecticides To Fight Vector-Borne Diseases.” Health Affairs (Project Hope) 36, no. 8 (August 2017): 1461–68. https://doi.org/10.1377/hlthaff.2016.1640.
    Full Text
  - Yurukoglu, A., E. Liebman, and D. B. Ridley. “The role of government reimbursement in drug shortages.” American Economic Journal: Economic Policy 9, no. 2 (May 1, 2017): 348–82. https://doi.org/10.1257/pol.20160035.
    Full Text Open Access Copy
  - Ridley, D. B., and S. Zhang. “Regulation of price increases.” International Journal of Industrial Organization 50 (January 1, 2017): 186–213. https://doi.org/10.1016/j.ijindorg.2016.11.004.
    Full Text
  - Ridley, David B. “Priorities for the Priority Review Voucher.” The American Journal of Tropical Medicine and Hygiene 96, no. 1 (January 2017): 14–15. https://doi.org/10.4269/ajtmh.16-0600.
    Full Text Open Access Copy
  - Basu, Anirban, Kirsten Axelsen, David C. Grabowski, David O. Meltzer, Daniel Polsky, David B. Ridley, Daniel Wiederkehr, and Tomas J. Philipson. “Real-World Data: Policy Issues Regarding their Access and Use.” Medical Care 54, no. 12 (December 2016): 1038–44. https://doi.org/10.1097/mlr.0000000000000603.
    Full Text
  - Basu, Anirban, Kirsten Axelsen, David C. Grabowski, David O. Meltzer, Daniel Polsky, David B. Ridley, Daniel Wiederkehr, and Tomas J. Philipson. “Real-World Data: Responses to Zito and Doshi.” Medical Care 54, no. 12 (December 2016): 1048–49. https://doi.org/10.1097/mlr.0000000000000655.
    Full Text
  - Ridley, David B., and Su Zhang. “Regulation of Price Increases,” August 22, 2016.
  - Ridley, David B., and Stephane A. Régnier. “The Commercial Market For Priority Review Vouchers.” Health Affairs (Project Hope) 35, no. 5 (May 2016): 776–83. https://doi.org/10.1377/hlthaff.2015.1314.
    Full Text
  - Ridley, David B., Jennifer Dent, and Christopher Egerton-Warburton. “Efficacy of the Priority Review Voucher Program.” Jama 315, no. 15 (April 2016): 1659–60. https://doi.org/10.1001/jama.2016.0377.
    Full Text
  - Ridley, David B., Xiaoshu Bei, and Eli B. Liebman. “No Shot: US Vaccine Prices And Shortages.” Health Affairs (Project Hope) 35, no. 2 (February 2016): 235–41. https://doi.org/10.1377/hlthaff.2015.0420.
    Full Text
  - Regnier, Stephane A., and David B. Ridley. “Market watch: Forecasting market share in the US pharmaceutical market.” Nature Reviews. Drug Discovery 14, no. 9 (September 2015): 594–95. https://doi.org/10.1038/nrd4697.
    Full Text
  - Regnier, Stephane Alexandre, and David B. Ridley. “Forecasting Market Share in the US Pharmaceutical Market.” Nature Reviews Drug Discovery. 2015. 14, no. 9 (July 31, 2015).
  - Arcidiacono, P., P. B. Ellickson, P. Landry, and D. B. Ridley. “Pharmaceutical followers.” International Journal of Industrial Organization 31, no. 5 (November 15, 2013): 538–53. https://doi.org/10.1016/j.ijindorg.2013.10.005.
    Full Text
  - Arcidiacono, Peter, Paul B. Ellickson, Peter Landry, and David B. Ridley. “Pharmaceutical Followers,” October 2013.
  - Gans, J. S., and D. B. Ridley. “Innovation incentives under transferable fast-track regulatory review.” Journal of Industrial Economics 61, no. 3 (September 1, 2013): 789–816. https://doi.org/10.1111/joie.12026.
    Full Text
  - Ridley, D. B. “Payments, promotion, and the purple pill (Accepted).” Health Economics (United Kingdom), 2013. https://doi.org/10.1002/hec.3005.
    Full Text
  - Ridley, David B., and Alfonso Calles Sánchez. “Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.” Lancet 376, no. 9744 (September 11, 2010): 922–27. https://doi.org/10.1016/S0140-6736(10)60669-1.
    Full Text Link to Item
  - Picone, G. A., D. B. Ridley, and P. A. Zandbergen. “Distance decreases with differentiation: Strategic agglomeration by retailers.” International Journal of Industrial Organization 27, no. 3 (May 1, 2009): 463–73. https://doi.org/10.1016/j.ijindorg.2008.11.007.
    Full Text
  - Moe, Jeffrey, Henry Grabowski, and David Ridley. “FDA review vouchers.” The New England Journal of Medicine 360, no. 8 (February 2009): 837. https://doi.org/10.1056/nejmc086492.
    Full Text
  - Ridley, D. B. “Herding versus Hotelling: Market entry with costly information.” Journal of Economics and Management Strategy 17, no. 3 (September 1, 2008): 607–31. https://doi.org/10.1111/j.1530-9134.2008.00188.x.
    Full Text
  - Ridley, David B. “International price comparisons for novel and follow-on drugs.” Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research 10, no. 6 (November 2007): 510–11. https://doi.org/10.1111/j.1524-4733.2007.00238.x.
    Full Text
  - Kyle, Margaret K., and David B. Ridley. “Would greater transparency and uniformity of health care prices benefit poor patients?” Health Affairs (Project Hope) 26, no. 5 (September 2007): 1384–91. https://doi.org/10.1377/hlthaff.26.5.1384.
    Full Text
  - Grabowski, H. G., D. B. Ridley, and K. A. Schulman. “Entry and competition in generic biologics.” Managerial and Decision Economics 28, no. 4–5 (June 1, 2007): 439–51. https://doi.org/10.1002/mde.1352.
    Full Text Open Access Copy
  - Ridley, David B., Judith M. Kramer, Hugh H. Tilson, Henry G. Grabowski, and Kevin A. Schulman. “Spending on postapproval drug safety.” Health Aff (Millwood) 25, no. 2 (March 2006): 429–36. https://doi.org/10.1377/hlthaff.25.2.429.
    Full Text Open Access Copy Link to Item
  - Ridley, D. B., and J. M. Kramer. “Postapproval drug safety: The authors respond [8].” Health Affairs 25, no. 4 (January 1, 2006): 1187–88. https://doi.org/10.1377/hlthaff.25.4.1184-a.
    Full Text
  - Ridley, David B., and Kirsten J. Axelsen. “Impact of Medicaid preferred drug lists on therapeutic adherence.” Pharmacoeconomics 24 Suppl 3 (January 2006): 65–78. https://doi.org/10.2165/00019053-200624003-00006.
    Full Text
  - Ridley, David B., Henry G. Grabowski, and Jeffrey L. Moe. “Developing drugs for developing countries.” Health Aff (Millwood) 25, no. 2 (2006): 313–24. https://doi.org/10.1377/hlthaff.25.2.313.
    Full Text Open Access Copy Link to Item
  - Ridley, David B., and Judith M. Kramer. “Postapproval drug safety: The authors respond.” Health Affairs 25, no. 4 (2006): 1187–88. https://doi.org/10.1377/hlthaff.25.4.1187.
    Full Text Link to Item
  - Ridley, David B. “Price differentiation and transparency in the global pharmaceutical marketplace.” Pharmacoeconomics 23, no. 7 (January 2005): 651–58. https://doi.org/10.2165/00019053-200523070-00002.
    Full Text
  - Ridley, David B., and Kevin A. Schulman. “Differential pricing of pharmaceuticals in the internet age.” The Journal of Ambulatory Care Management 27, no. 3 (July 2004): 210–14. https://doi.org/10.1097/00004479-200407000-00004.
    Full Text
  - Shah, Bimal R., Shelby D. Reed, Jennifer Francis, David B. Ridley, and Kevin A. Schulman. “The cost of inefficiency in US hospitals, 1985-1997.” J Health Care Finance 30, no. 1 (2003): 1–9.
    Link to Item
  - Ridley, David B. “Herding versus Hotelling: Market Entry with Costly Information,” n.d.
Teaching & Mentoring
Recent Courses

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

In the News

Subject Headings

Selected Grants

Selected Publications

Academic Articles

Recent Courses